Katherine E Brick1, Chad H Weaver1, Rodolfo Savica2, Christine M Lohse3, Mark R Pittelkow4, Bradley F Boeve5, Lawrence E Gibson6, Michael J Camilleri6, Carilyn N Wieland7. 1. Department of Dermatology, Mayo Clinic, Rochester, Minnesota. 2. Department of Neurology, Division of Sleep and Movement Disorders, University of Utah, Salt Lake City, Utah. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. Department of Dermatology, Mayo Clinic, Scottsdale, Arizona. 5. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 6. Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota. 7. Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: wieland.carilyn@mayo.edu.
Abstract
BACKGROUND: Bullous pemphigoid (BP) has been associated with neurologic disorders. OBJECTIVE: We sought to analyze the association between BP and neurologic disorders. METHODS: We retrospectively identified residents of Olmsted County, Minnesota, with a first lifetime diagnosis of BP between January 1, 1960, and December 31, 2009. Three age- and sex-matched Olmsted County, Minnesota, residents without BP were selected as control subjects for each patient. We compared history of or development of neurologic disorders (dementia, Alzheimer disease, Parkinson disease, multiple sclerosis, cerebrovascular disease, and seizures) between groups using case-control and cohort designs. RESULTS: In all, 87 patients with BP were identified and matched to 261 control subjects. The odds of a previous diagnosis of any neurologic disorder or a history of dementia were significantly increased among cases compared with controls (odds ratio 6.85; 95% confidence interval [CI] 3.00-15.64; P < .001; and odds ratio 6.75; 95% CI 2.08-21.92; P = .002, respectively). Both Parkinson disease (hazard ratio 8.56; 95% CI 1.55-47.25; P = .01) and any type of neurologic disorder (hazard ratio 2.02; 95% CI 1.17-3.49; P = .01) were significantly more likely to develop during follow-up in patients with than without BP. LIMITATIONS: Small geographic area and retrospective study design are limitations. CONCLUSION: Findings confirmed an association of BP with neurologic disorders, especially dementia and Parkinson disease.
BACKGROUND: Bullous pemphigoid (BP) has been associated with neurologic disorders. OBJECTIVE: We sought to analyze the association between BP and neurologic disorders. METHODS: We retrospectively identified residents of Olmsted County, Minnesota, with a first lifetime diagnosis of BP between January 1, 1960, and December 31, 2009. Three age- and sex-matched Olmsted County, Minnesota, residents without BP were selected as control subjects for each patient. We compared history of or development of neurologic disorders (dementia, Alzheimer disease, Parkinson disease, multiple sclerosis, cerebrovascular disease, and seizures) between groups using case-control and cohort designs. RESULTS: In all, 87 patients with BP were identified and matched to 261 control subjects. The odds of a previous diagnosis of any neurologic disorder or a history of dementia were significantly increased among cases compared with controls (odds ratio 6.85; 95% confidence interval [CI] 3.00-15.64; P < .001; and odds ratio 6.75; 95% CI 2.08-21.92; P = .002, respectively). Both Parkinson disease (hazard ratio 8.56; 95% CI 1.55-47.25; P = .01) and any type of neurologic disorder (hazard ratio 2.02; 95% CI 1.17-3.49; P = .01) were significantly more likely to develop during follow-up in patients with than without BP. LIMITATIONS: Small geographic area and retrospective study design are limitations. CONCLUSION: Findings confirmed an association of BP with neurologic disorders, especially dementia and Parkinson disease.
Authors: Y J Chen; C Y Wu; M W Lin; T J Chen; K K Liao; Y C Chen; C Y Hwang; S Y Chu; C C Chen; D D Lee; Y T Chang; W J Wang; H N Liu Journal: Br J Dermatol Date: 2011-07-28 Impact factor: 9.302
Authors: Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: Eoin P Flanagan; Andrew McKeon; Vanda A Lennon; Bradley F Boeve; Max R Trenerry; K Meng Tan; Daniel A Drubach; Keith A Josephs; Jeffrey W Britton; Jayawant N Mandrekar; Val Lowe; Joseph E Parisi; Sean J Pittock Journal: Mayo Clin Proc Date: 2010-10 Impact factor: 7.616
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Kyle T Amber; Christine M Panganiban; Dorota Korta; Sebastien de Feraudy; Kristen M Kelly; Sergei A Grando Journal: Melanoma Res Date: 2017-02 Impact factor: 3.599
Authors: Anna-Kaisa Försti; Jari Jokelainen; Hanna Ansakorpi; Allan Seppänen; Kari Majamaa; Markku Timonen; Kaisa Tasanen Journal: Sci Rep Date: 2016-11-15 Impact factor: 4.379